QUOTE AND NEWS
Wall Street Journal  Jan 28  Comment 
The drug giants won European Union regulatory approval for a complicated series of deals worth more than $20 billion that will focus Novartis’ scope and turn Glaxo into a vaccines-and-consumer-drug powerhouse.
FiercePharma  Jan 28  Comment 
Novartis' Cosentyx may be the first next-gen psoriasis treatment to hit the U.S. market, but it certainly won't be the last--and the Swiss drugmaker knows it. So while competitors usher their own prospects down the regulatory pathway, the company...
FierceBiotech  Jan 28  Comment 
Novartis has admitted that sales of the vitreomacular adhesion drug it licensed from ThromboGenics have failed to live up to expectations. And while various theories have been put forward to explain the drug's relative lack of commercial success,...
TheStreet.com  Jan 27  Comment 
NEW YORK (TheStreet) -- Novartis AG shares are up 2.64% to $99.04 in trading on Tuesday after the drug maker reported its fourth quarter earnings results before the opening bell today. The company reported a 26% decline in profit from the...
FiercePharma  Jan 27  Comment 
Novartis is looking for big things as it doubles down in oncology, hives off vaccines, and teams up with GlaxoSmithKline on consumer health. It's looking for impressive results from its new meds, especially its forthcoming heart failure drug...
FierceBiotech  Jan 27  Comment 
Three of the world's largest drugmakers dialed up their R&D budgets in 2014, as Novartis, Pfizer and Bristol-Myers Squibb spent big on costly late-stage programs with hopes of delivering blockbuster new treatments in the coming year.
GenEng News  Jan 27  Comment 
Three pharma giants this morning reported mixed fourth-quarter 2014 results, showing mostly declines in earnings and revenues results, as well as significant sales surges for some drugs, particularly cancer treatments. Bristol-Myers Squibb...
Financial Times  Jan 27  Comment 
Swiss pharma group says soaring franc will hit profits, but backs central bank move




 

Fuerralz? That's marvelously good to know.

Wikinvest © 2006, 2007, 2008, 2009, 2010, 2011, 2012. Use of this site is subject to express Terms of Service, Privacy Policy, and Disclaimer. By continuing past this page, you agree to abide by these terms. Any information provided by Wikinvest, including but not limited to company data, competitors, business analysis, market share, sales revenues and other operating metrics, earnings call analysis, conference call transcripts, industry information, or price targets should not be construed as research, trading tips or recommendations, or investment advice and is provided with no warrants as to its accuracy. Stock market data, including US and International equity symbols, stock quotes, share prices, earnings ratios, and other fundamental data is provided by data partners. Stock market quotes delayed at least 15 minutes for NASDAQ, 20 mins for NYSE and AMEX. Market data by Xignite. See data providers for more details. Company names, products, services and branding cited herein may be trademarks or registered trademarks of their respective owners. The use of trademarks or service marks of another is not a representation that the other is affiliated with, sponsors, is sponsored by, endorses, or is endorsed by Wikinvest.
Powered by MediaWiki